These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 6372758)
1. Amantadine in the treatment of Creutzfeldt-Jakob disease. Braham J Arch Neurol; 1984 Jun; 41(6):585-6. PubMed ID: 6372758 [No Abstract] [Full Text] [Related]
2. Creutzfeldt-Jakob disease with focal onset unsuccessfully treated with amantadine. Ratcliffe J; Rittman A; Wolf S; Verity MA Bull Los Angeles Neurol Soc; 1975 Jan; 40(1):18-20. PubMed ID: 1097004 [No Abstract] [Full Text] [Related]
3. [Amantadine in Creutzfeldt-Jakob disease. Review of the literature and case contribution]. Neri G; Figà-Talamanca L; Di Battista GC; Lo Russo F Riv Neurobiol; 1984; 30(1):47-56. PubMed ID: 6399949 [No Abstract] [Full Text] [Related]
13. Possible association between triphasic E.E.G. waves and disorder of dopaminergic systems. Hamoen AM Br Med J; 1973 Aug; 3(5874):272-3. PubMed ID: 4579292 [TBL] [Abstract][Full Text] [Related]
17. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Benito-León J Neurology; 2005 May; 64(10):1824; author reply 1824. PubMed ID: 15911834 [No Abstract] [Full Text] [Related]
18. [Therapeutic approaches for treatment of Creutzfeldt-Jakob disease]. Heinemann U; Weiss S; Zerr I Med Monatsschr Pharm; 2008 Oct; 31(10):378-84. PubMed ID: 18972868 [TBL] [Abstract][Full Text] [Related]
19. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Collins SJ; Lewis V; Brazier M; Hill AF; Fletcher A; Masters CL Ann Neurol; 2002 Oct; 52(4):503-6. PubMed ID: 12325081 [TBL] [Abstract][Full Text] [Related]